Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- North Shore University Hospital — Manhasset, New York
- Long Island Jewish Medical Center — New Hyde Park, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting NIH
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in New York: - University of Rochester — Rochester, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in New York: - Glens Falls Hospital — Glens Falls, New York
- University of Rochester — Rochester, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in New York: - Albany Medical Center — Albany, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in New York: - New York Oncology Hematology, P.C. ( Site 0129) — Albany, New York
- Icahn School of Medicine at Mount Sinai ( Site 0164) — New York, New York
- New York Cancer and Blood Specialists ( Site 9000) — Shirley, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in New York: - Columbia University Medical Center — New York, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in New York: - Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in New York: - New York Oncology Hematology, P.C. ( Site 5453) — Albany, New York
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in New York: - NYU Langone's Perlmutter Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Optum Medical Care, PC — Westbury, New York
Phase 3 Recruiting Industry
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primar…
Sponsor: Kite, A Gilead Company
NCT ID: NCT07479797
Sites in New York: - Weill Cornell Medicine-NewYork-Presbyterian Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in New York: - Mount Sinai Medical Center — New York, New York
Phase 3 Recruiting Industry
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (C…
Sponsor: CSL Behring
NCT ID: NCT07648264
Sites in New York: - David H. Koch Center for Cancer Care — New York, New York
- Montefiore Medical Center PRIME — The Bronx, New York
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Margina…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in New York: - Stony Brook University Hospital — Stony Brook, New York
- Clinical Research Alliance Inc — Westbury, New York
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in New York: - Albany Medical Center — Albany, New York
- Maimonides Medical Center — Brooklyn, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- University of Rochester — Rochester, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- NYP/Weill Cornell Medical Center — New York, New York
- University of Rochester — Rochester, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 2 Recruiting NIH
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Medical College — Valhalla, New York
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Mount Sinai Hospital — New York, New York
- Columbia University — New York, New York
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion coho…
Sponsor: Syndax Pharmaceuticals
NCT ID: NCT04065399
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — New York, New York